Effects of restrictive reimbursement on the prescribing and expenditures on non-essential lipid-lowering drugs

Research in Social and Administrative Pharmacy - Tập 16 - Trang 1664-1669 - 2020
Chulaporn Limwattananon1, Cheardchai Soontornpas1, Onanong Waleekhachonloet2, Thananan Rattanachotphanit2, Noppakun Thammatacharee3
1Division of Clinical Pharmacy, Faculty of Pharmaceutical Sciences, Khon Kaen University, Khon Kaen, Thailand
2Department of Clinical Pharmacy, Faculty of Pharmacy, Mahasarakham University, Mahasarakham, Thailand
3Health Systems Research Institute, Nonthaburi, Thailand

Tài liệu tham khảo

Vasavid, 2012, Thai national health accounts Part 1: Thai health expenditure 1994-2008, J Health Sci, 21, 1073

Limwattananon, 2015, Chapter 7: assessment of the health system

National List of Essential Medicine

Yoongthong, 2012, National drug policies to local formulary decisions in Thailand, China, and Australia: drug listing changes and opportunities, Value Health, 15, S126, 10.1016/j.jval.2011.11.003

Limwattananon, 2011, Expenditure of Civil servant medical benefit scheme and the use of non-essential medicines, J Health Syst Res, 5, 149

Comptroller General’s Department, Ministry of Finance. Letters to Hospital Directors: Criteria for Reimbursement of Non-essential Drugs in Civil Servant Medical Benefit Scheme. Number 0422/Wor 143 (dated 19 April 2010) (Thai).

Yoo, 2015, Effects of drug price reduction and prescribing restrictions on expenditures and utilisation of antihypertensive drugs in Korea, BMJ Open, 5, 10.1136/bmjopen-2014-006940

Fischer, 2007, Angiotensin-receptor blockers: can policy promote rational prescribing?, Health Aff, 26, 800, 10.1377/hlthaff.26.3.800

Bjerrum, 2001, Guidelines accompanied by changes in reimbursement rules: effects on lipid-lowering drug prescribing, Scand J Prim Health Care, 19, 158, 10.1080/028134301316982379

Sakshaug, 2007, Switching statins in Norway after new reimbursement policy – a nationwide prescription study, Br J Clin Pharmacol, 4, 476, 10.1111/j.1365-2125.2007.02907.x

Limwattananon, 2011, Potential saving from setting reimbursable rates of outpatient drugs for Civil Servant Medical Benefit Scheme in 2010, J Health Syst Res, 5, 160

2015

Lagarde, 2012, How to do (or not to do) Assessing the impact of a policy change with routine longitudinal data, Health Pol Plann, 27, 76, 10.1093/heapol/czr004

Prais, 1954

MacCara, 2001, Impact of a limited fluoroquinolone reimbursement policy on antimicrobial prescription claims, Ann Pharmacother, 35, 852, 10.1345/aph.10272